It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore the distinctive challenges and promising advancements in paediatric oncology. Uncover innovative approaches shaping better outcomes for childhood cancers, reflecting our commitment to comprehensive and compassionate drug discovery.
Medicinal chemists’ inventions go beyond creating molecules; they impact patients. Wide collaboration in design teams enhances patent quality. Routine patent reviews keep us competitive.
Discover how Sygnature Discovery integrates machine learning into HPLC purification, transforming a data-heavy process into a streamlined, automated workflow. This innovation achieves 95% method selection accuracy, saving time and ensuring high-quality compounds for clients.
Metaflammation fuels the global rise of metabolic diseases, including obesity and type 2 diabetes. Explore the intricate connection between chronic inflammation and these conditions, uncovering potential pharmacological strategies for managing meta-inflammation.
Delve into drug discovery’s dynamic blend of logic and learning, where Pasteur’s foresight meets the bold pursuit of serendipitous opportunities. From crafting hypotheses to exploring unexpected outcomes, a prepared mind navigates the intricate path toward transformative breakthroughs, ensuring each discovery is a pivotal step toward the next generation of therapeutics.
Over the last decade, GLP-1 therapies have transformed diabetes and obesity treatment. Discover the potential of small molecules in this field and their role in revolutionizing treatment options and improving patient outcomes.
Dive into the world of neuroinflammation research, featuring insights on in vitro models, in vivo testing, and stay updated with upcoming presentations at the Society for Neuroscience (SfN) event. Explore the latest in CNS drug discovery and innovation.
Dive into the world of 5-HT2A receptor modulation, DMPK, and novel psychedelics. Learn how these aspects impact therapeutic responses and discover our exciting research at SfN 2023.
